In this issue, Palmer and co-workers present their experience with gaining approval for and the introduction of intravenous paracetamol in a tertiary paediatric hospital 1 . Their paper raises two important issues. The first is the safety concern associated with new drug formulations in special populations. Most drugs marketed in Australia have already been extensively used overseas prior to their arrival on our shores, giving us a general feeling that any serious adverse effects will have already been identified. While this is true in the main, experience may be limited in special populations such as the very young, the elderly and those with a range of co-morbidities.
In the case of intravenous paracetamol, it is clear that this product is an exceptionally useful addition to our armamentarium that can provide a reliable pharmacokinetic profile when compared to the use of rectal products. Yet safety concerns remain since, as the authors point out, paracetamol toxicity has been reported in children even when the drug is prescribed according to accepted guidelines. Intravenous administration results in peak plasma levels considerably higher than those seen with oral or rectal administration. While this might seem to be of no great concern, it is only by following the use of the drug in large populations that this can be confirmed. It is up all of us to use appropriate audit tools to map not only efficacy, but also adverse events that follow the introduction of new drugs. As usage increases, it is a matter of statistical inevitability that adverse events will emerge and these must be reported.
The second theme addressed in the article is the role of the Hospital Drug and Therapeutics Committee (DTC) in approving new products. Often seen as reactionary and obstructive, DTCs play the gatekeeper role in releasing new products at a local level. Although decision making can sometimes be seen as somewhat ad hoc, a recent study of DTCs in Australia by Tan et al 2 found that the parameters used by committees across the country to guide decisions on drug approval were remarkably constant. Patient safety was the key concern, followed by the need for decisions to be evidence-based, financial considerations and satisfaction of legal requirements. Financial considerations of course, rarely work in favour of new drugs. Every new analgesic will perforce be compared cost-wise with morphine and every new anti-emetic with metoclopramide. The benefits offered by new analgesics, that may cost an order of magnitude more than older agents, are usually based on an improved side-effect profile, reduced hospital stay or greater patient acceptability. These are difficult to measure and to quantify.
In the relation to the Palmer et al paper, their DTC was resistant to approve the drug on safety grounds. Interestingly, when the same product came before the DTC at my hospital, the Committee was prepared to approve it for paediatric use but our paediatricians suggested that the Committee withhold approval because of concerns of drug administration errors, multiple dosing and the fact that it had yet to be used in a major paediatric hospital. This serves to demonstrate that while individual DTCs may make different decisions concerning the same product, this is not unexpected, since hospital DTCs act as a microcosm of their own world, reflecting local concerns and local problems that will be specific to the hospital, staff and patient populations.
While DTCs must take the responsibility for initially granting drug approvals, it is up to all of us to undertake regular audits of new therapeutic agents and so contribute to the critical task of postmarketing surveillance. This is even more important where hospitals serve specialty patient populations, as is well demonstrated by Palmer et al. 
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